GLPwatch
Diarrhea
27,967 FAERS reports across 12 drugs
Last updated 2026-07-12 06:04 UTCDiarrhea is when someone has loose, watery stools more often than usual.
Plain-language definition of the term.
Diarrhea is listed as an adverse reaction in the FDA labels for Byetta, Mounjaro, Ozempic, Rybelsus, Saxenda, Soliqua, Trulicity, Victoza, Wegovy, Xultophy, and Zepbound, and is also mentioned in the warnings and cautions sections for these GLP-1 drugs.
AI summary of the sources below.
FAERS report counts (as of 2026Q2) reflect voluntary adverse-event reports and cannot establish causation or true frequency; higher counts often track prescription volume. openFDA FAERS ↗
Reports by drug
| Drug | FAERS reports | Quarter |
|---|---|---|
| Trulicity | 5,821 | 2026Q2 |
| Ozempic | 5,274 | 2026Q2 |
| Mounjaro | 5,180 | 2026Q2 |
| Victoza | 2,994 | 2026Q2 |
| Zepbound | 2,938 | 2026Q2 |
| Byetta | 2,747 | 2026Q2 |
| Bydureon | 1,100 | 2026Q2 |
| Wegovy | 802 | 2026Q2 |
| Rybelsus | 531 | 2026Q2 |
| Saxenda | 414 | 2026Q2 |
| Xultophy | 87 | 2026Q2 |
| Soliqua | 79 | 2026Q2 |
Mentioned in FDA labels
Research mentioning diarrhea (13)
- Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
- Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial.
- Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11.
- Managing bile acid diarrhea: aspects of contention.
- Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea.
- Liraglutide and Colesevelam Change Serum and Fecal Bile Acid Levels in a Randomized Trial With Patients With Bile Acid Diarrhea.
- Treating bile acid diarrhoea with liraglutide.
- Treatment of Bile Acid Diarrhea With Glucagon-Like Peptide 1 Receptor Agonists: A Promising Yet Understudied Approach.
- A case for screening real-world data for collateral drug benefits: Glucagon-like peptide 1 receptor agonists and bile acid diarrhea.
- Semaglutide for treatment of intractable diarrhea of different etiologies: a case series of 30 patients.
- Liraglutide versus colesevelam for treating bile acid diarrhoea.
- Bile acid diarrhoea.
- Liraglutide versus colesevelam for treating bile acid diarrhoea - Authors' reply.